Brief: Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL in Parkinson’s Disease
05/11/2025 13:32
Nov 5 (Reuters) - Jupiter Neurosciences Inc JUNS.O: JUPITER NEUROSCIENCES RECEIVES FDA CLEARANCE OF IND APPLICATION TO INITIATE PHASE 2A CLINICAL TRIAL OF JOTROL™ IN PARKINSON’S DISEASE JUPITER NEUROSCIENCES INC - EXPECTS TRIAL ENROLLMENT TO BEGIN IN EARLY 2026 Source text: ID:nGNX3Bt1pV Further company coverage: JUNS.O ((Reuters.Briefs@thomsonreuters.com;))